Serina Therapeutics Secures $15M in Equity Financing, Advances POZ-lipid Technology in Q1 2025 Results
Serina Therapeutics Inc. reports Q1 2025 financial results, including $15 million in equity financing, board expansion, and advancements in its POZ-lipid technology.
2 minutes to read